Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VS-6063 maintenance trial in malignant pleural mesothelioma
NL-OMON40190Phase 2Recruiting
- Sponsor
- Verastem Oncology
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pleural mesothelioma comparing VS-6063 with Placebo (2 arms). Primary endpoints: Overall survival and Progression-free survival. Started Nov 2013; status: recruiting.
02
Drugs
defactinib
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on NL-OMON40190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40190.